2 Results for "

BG00002

" in MedChemExpress (MCE) Product Catalog:
Products (2)

2 Results for "BG00002" in MCE Product Catalog:

3
Natalizumab (Anti-CD49d)
Natalizumab (Anti-CD49d)
0 Images
3 Cited Publications
Cat. No.: HY-108831A
CAS No.: 189261-10-7
Purity:  98.72%
Synonyms: AN100226; BG00002

Target:  

Integrin

Research Areas:  

Neurological Disease Inflammation/Immunology Cancer

Natalizumab (Anti-CD49d) (AN100226; BG00002) Solution is a humanized monoclonal IgG4 antibody inhibitor that selectively targets α4 integrin (CD49d), blocking the interaction of integrins such as α4β1 (VLA-4) with vascular cell adhesion molecule VCAM-1, intercellular adhesion molecule ICAM-1, and fibronectin by competitively binding to the α4 subunit. Natalizumab solution inhibits the adhesion, retention, and transendothelial migration of immune cells (such as CD4 + T cells), reducing the infiltration of inflammatory cells into the central nervous system or lesion sites, thereby exerting anti-inflammatory and immunomodulatory activity. Natalizumab (Anti-CD49d) solution is used in the study of relapsing-remitting multiple sclerosis (RRMS) and is also applied in the research of autoimmune or inflammation-related diseases such as Crohn's disease, B-cell lymphoma, and non-infectious uveitis. Natalizumab (Anti-CD49d) can also prevent lymphocytes from entering the central nervous system, thus preventing acute demyelinating relapses .
loading...
    loading...
View All Sizes
3
Natalizumab
Natalizumab
0 Images
3 Cited Publications
Cat. No.: HY-108831
CAS No.: 189261-10-7
Purity:  99.10%

Target:  

Integrin

Research Areas:  

Neurological Disease Inflammation/Immunology Cancer

Natalizumab (AN100226; BG00002) is a humanized monoclonal IgG4 antibody inhibitor that selectively targets α4 integrin (CD49d). It blocks the interaction of integrins such as α4β1 (VLA-4) with vascular cell adhesion molecule VCAM-1, intercellular adhesion molecule ICAM-1, and fibronectin by competitively binding to the α4 subunit. Natalizumab inhibits the adhesion, retention, and transendothelial migration of immune cells (such as CD4 + T cells), reducing the infiltration of inflammatory cells into the central nervous system or lesion sites, thus exerting anti-inflammatory and immunomodulatory activity. Natalizumab is used in the study of relapsing-remitting multiple sclerosis (RRMS) and also has applications in the study of autoimmune or inflammation-related diseases such as Crohn's disease, B-cell lymphoma, and non-infectious uveitis. Natalizumab can also prevent lymphocytes from entering the central nervous system, thereby preventing acute demyelinating relapses .
loading...
    loading...
View All Sizes
Assay Types